8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The pandemic associated with SARS-CoV-2 is a worldwide public health challenge. The WHO has proposed to achieve 70% COVID-19 vaccination coverage in all countries by mid-2022. Nevertheless, the prevention strategy based on COVID-19 vaccination and other applied prevention measures has not been sufficient to prevent SARS-CoV-2 epidemic waves. This study assessed the vaccination coverage that would be required to establish herd immunity against SARS-CoV-2, taking into account virus transmissibility (Ro values from 1.1 to 10) and COVID-19 vaccination effectiveness. The study found that high percentages of vaccination coverage and high levels of vaccination effectiveness are necessary to block the transmission of Omicron and other SARS-CoV-2 variants with greater infectious capacity. COVID-19 vaccination programs could establish herd immunity against SARS-CoV-2, with Ro values ranging from 3 to 10 and levels of COVID-19 vaccination effectiveness of 70-100%. Factors reducing COVID-19 vaccination effectiveness (emergent variants, infections among vaccinated individuals, high risk individuals) and factors increasing SARS-CoV-2 transmissibility (close settings) increased the percentages of vaccination coverage that would be required to establish herd immunity. Two measures should be implemented to establish herd immunity against SARS-CoV-2: (1) achieve ≥ 90% COVID-19 vaccination coverage in all countries worldwide, and (2) increase the effectiveness of COVID-19 vaccines in preventing Omicron infection to at least 88%.

          Related collections

          Author and article information

          Journal
          Vaccines (Basel)
          Vaccines
          MDPI AG
          2076-393X
          2076-393X
          May 08 2022
          : 10
          : 5
          Affiliations
          [1 ] Public Health Agency of Catalonia, Department of Health of Catalonia, 08005 Barcelona, Spain.
          [2 ] Ciber of Epidemiology and Public Health (CIBERESP), 28028 Madrid, Spain.
          Article
          vaccines10050736
          10.3390/vaccines10050736
          9144560
          35632492
          fbf9767a-1f86-496f-a46b-15df89ed4b01
          History

          anti-SARS-CoV-2 herd immunity,SARS-CoV-2,COVID-19 vaccination strategy,COVID-19 vaccination coverage

          Comments

          Comment on this article